REVISIÓN
Uso de fármacos biológicos en dermatosis fuera de la indicación aprobada. Segunda parte: etanercept, efalizumab, alefacept, rituximab, daclizumab, basiliximab, omalizumab y cetuximab
Off-label use of biologic agents in the treatment of dermatosis, part 2: etanercept, efalizumab, alefacept, rituximab, daclizumab, basiliximab, omalizumab, and cetuximab
G. Guhl†
, B. Díaz-Ley, J. Fernández-Herrera
Autor para correspondencia
guhl@aedv.es
Guillermo Guhl Millán. Servicio de Dermatología. Hospital Universitario de la Princesa. Diego de León, 62. 28006 Madrid. España.
Guillermo Guhl Millán. Servicio de Dermatología. Hospital Universitario de la Princesa. Diego de León, 62. 28006 Madrid. España.
Servicio de Dermatología. Hospital Universitario de la Princesa. Madrid. España
Leído
18880
Vecesse ha leído el artículo
3480
Total PDF
15400
Total HTML
| año/Mes | Html | Total | |
|---|---|---|---|
| 2025 6 | 122 | 35 | 157 |
| 2025 5 | 185 | 30 | 215 |
| 2025 4 | 163 | 29 | 192 |
| 2025 3 | 157 | 44 | 201 |
| 2025 2 | 153 | 39 | 192 |
| 2025 1 | 179 | 50 | 229 |
| 2024 12 | 159 | 32 | 191 |
| 2024 11 | 106 | 66 | 172 |
| 2024 10 | 106 | 55 | 161 |
| 2024 9 | 107 | 49 | 156 |
| 2024 8 | 127 | 78 | 205 |
| 2024 7 | 140 | 49 | 189 |
| 2024 6 | 153 | 42 | 195 |
| 2024 5 | 104 | 40 | 144 |
| 2024 4 | 120 | 34 | 154 |
| 2024 3 | 123 | 53 | 176 |
| 2024 2 | 107 | 49 | 156 |
| 2024 1 | 116 | 31 | 147 |
| 2023 12 | 130 | 30 | 160 |
| 2023 11 | 147 | 34 | 181 |
| 2023 10 | 131 | 28 | 159 |
| 2023 9 | 115 | 26 | 141 |
| 2023 8 | 86 | 26 | 112 |
| 2023 7 | 116 | 48 | 164 |
| 2023 6 | 101 | 30 | 131 |
| 2023 5 | 24 | 12 | 36 |
| 2023 4 | 66 | 24 | 90 |
| 2023 3 | 89 | 42 | 131 |
| 2023 2 | 94 | 27 | 121 |
| 2022 1 | 70 | 24 | 94 |
| 2022 12 | 67 | 34 | 101 |
| 2022 11 | 127 | 32 | 159 |
| 2022 10 | 73 | 51 | 124 |
| 2022 9 | 59 | 54 | 113 |
| 2022 8 | 52 | 32 | 84 |
| 2022 7 | 49 | 36 | 85 |
| 2022 6 | 62 | 35 | 97 |
| 2022 5 | 82 | 35 | 117 |
| 2022 4 | 89 | 40 | 129 |
| 2022 3 | 48 | 53 | 101 |
| 2022 2 | 80 | 36 | 116 |
| 2021 1 | 52 | 46 | 98 |
| 2021 12 | 55 | 54 | 109 |
| 2021 11 | 77 | 29 | 106 |
| 2021 10 | 93 | 58 | 151 |
| 2021 9 | 63 | 36 | 99 |
| 2021 8 | 67 | 26 | 93 |
| 2021 7 | 61 | 20 | 81 |
| 2021 6 | 53 | 41 | 94 |
| 2021 5 | 62 | 30 | 92 |
| 2021 4 | 75 | 39 | 114 |
| 2021 3 | 72 | 71 | 143 |
| 2021 2 | 74 | 29 | 103 |
| 2020 1 | 47 | 20 | 67 |
| 2020 12 | 47 | 12 | 59 |
| 2020 11 | 38 | 23 | 61 |
| 2020 10 | 32 | 21 | 53 |
| 2020 9 | 18 | 9 | 27 |
| 2020 8 | 21 | 22 | 43 |
| 2020 7 | 32 | 14 | 46 |
| 2020 6 | 32 | 30 | 62 |
| 2020 5 | 44 | 44 | 88 |
| 2020 4 | 29 | 23 | 52 |
| 2020 3 | 31 | 12 | 43 |
| 2020 2 | 1 | 0 | 1 |
| 2019 11 | 7 | 0 | 7 |
| 2019 8 | 2 | 4 | 6 |
| 2019 6 | 1 | 0 | 1 |
| 2019 5 | 3 | 1 | 4 |
| 2019 4 | 1 | 0 | 1 |
| 2019 3 | 6 | 9 | 15 |
| 2019 2 | 1 | 1 | 2 |
| 2019 1 | 3 | 8 | 11 |
| 2018 12 | 3 | 0 | 3 |
| 2018 11 | 4 | 2 | 6 |
| 2018 10 | 1 | 0 | 1 |
| 2018 9 | 5 | 0 | 5 |
| 2018 8 | 1 | 0 | 1 |
| 2018 6 | 1 | 0 | 1 |
| 2018 3 | 3 | 1 | 4 |
| 2018 2 | 44 | 7 | 51 |
| 2018 1 | 42 | 7 | 49 |
| 2017 12 | 51 | 14 | 65 |
| 2017 11 | 44 | 8 | 52 |
| 2017 10 | 40 | 7 | 47 |
| 2017 9 | 60 | 10 | 70 |
| 2017 8 | 58 | 8 | 66 |
| 2017 7 | 42 | 6 | 48 |
| 2017 6 | 61 | 9 | 70 |
| 2017 5 | 61 | 6 | 67 |
| 2017 4 | 51 | 5 | 56 |
| 2017 3 | 64 | 21 | 85 |
| 2017 2 | 132 | 5 | 137 |
| 2016 1 | 33 | 6 | 39 |
| 2016 12 | 63 | 9 | 72 |
| 2016 11 | 101 | 11 | 112 |
| 2016 10 | 113 | 10 | 123 |
| 2016 9 | 170 | 9 | 179 |
| 2016 8 | 159 | 8 | 167 |
| 2016 7 | 61 | 5 | 66 |
| 2016 6 | 10 | 7 | 17 |
| 2016 5 | 4 | 9 | 13 |
| 2016 4 | 9 | 4 | 13 |
| 2016 3 | 5 | 3 | 8 |
| 2016 2 | 6 | 4 | 10 |
| 2015 1 | 6 | 22 | 28 |
| 2015 12 | 9 | 6 | 15 |
| 2015 11 | 14 | 14 | 28 |
| 2015 10 | 17 | 11 | 28 |
| 2015 9 | 14 | 13 | 27 |
| 2015 8 | 11 | 10 | 21 |
| 2015 7 | 286 | 1 | 287 |
| 2015 6 | 242 | 17 | 259 |
| 2015 5 | 336 | 35 | 371 |
| 2015 4 | 290 | 32 | 322 |
| 2015 3 | 345 | 21 | 366 |
| 2015 2 | 227 | 13 | 240 |
| 2015 1 | 199 | 10 | 209 |
| 2014 12 | 244 | 13 | 257 |
| 2014 11 | 233 | 11 | 244 |
| 2014 10 | 286 | 8 | 294 |
| 2014 9 | 233 | 15 | 248 |
| 2014 8 | 213 | 17 | 230 |
| 2014 7 | 233 | 14 | 247 |
| 2014 6 | 224 | 18 | 242 |
| 2014 5 | 195 | 18 | 213 |
| 2014 4 | 206 | 16 | 222 |
| 2014 3 | 165 | 39 | 204 |
| 2014 2 | 133 | 37 | 170 |
| 2014 1 | 149 | 11 | 160 |
| 2013 12 | 153 | 11 | 164 |
| 2013 11 | 126 | 20 | 146 |
| 2013 10 | 116 | 22 | 138 |
| 2013 9 | 106 | 16 | 122 |
| 2013 8 | 108 | 31 | 139 |
| 2013 7 | 134 | 84 | 218 |
| 2013 6 | 155 | 88 | 243 |
| 2013 5 | 141 | 82 | 223 |
| 2013 4 | 121 | 70 | 191 |
| 2013 3 | 153 | 28 | 181 |
| 2013 2 | 146 | 19 | 165 |
| 2013 1 | 185 | 8 | 193 |
| 2012 12 | 143 | 15 | 158 |
| 2012 11 | 128 | 10 | 138 |
| 2012 10 | 88 | 12 | 100 |
| 2012 9 | 56 | 15 | 71 |
| 2012 8 | 8 | 0 | 8 |
| 2011 5 | 23 | 0 | 23 |
| 2011 4 | 17 | 0 | 17 |
| 2011 3 | 57 | 0 | 57 |
| 2011 2 | 84 | 0 | 84 |
| 2010 1 | 133 | 0 | 133 |
| 2010 12 | 50 | 0 | 50 |
| 2010 11 | 191 | 0 | 191 |
| 2010 10 | 59 | 0 | 59 |
| 2010 9 | 19 | 0 | 19 |
| 2010 8 | 56 | 0 | 56 |
| 2010 7 | 78 | 0 | 78 |
| 2010 6 | 41 | 0 | 41 |
| 2010 5 | 120 | 0 | 120 |
| 2010 4 | 49 | 0 | 49 |
| 2010 3 | 24 | 0 | 24 |
| 2010 2 | 21 | 0 | 21 |
| 2009 1 | 15 | 0 | 15 |
| 2009 12 | 12 | 0 | 12 |
| 2009 11 | 69 | 0 | 69 |
| 2009 10 | 26 | 0 | 26 |
| 2009 9 | 28 | 0 | 28 |
| 2009 8 | 23 | 0 | 23 |
| 2009 7 | 27 | 0 | 27 |
| 2009 6 | 41 | 0 | 41 |
| 2009 5 | 33 | 0 | 33 |
| 2009 4 | 27 | 0 | 27 |
| 2009 3 | 28 | 0 | 28 |
| 2009 2 | 21 | 0 | 21 |
| 2009 1 | 19 | 0 | 19 |
| 2008 12 | 12 | 0 | 12 |
| 2008 11 | 31 | 0 | 31 |
| 2008 10 | 51 | 0 | 51 |
| 2008 9 | 79 | 0 | 79 |
| 2008 8 | 37 | 0 | 37 |
| 2008 7 | 46 | 0 | 46 |
| 2008 6 | 26 | 0 | 26 |
| 2008 5 | 46 | 0 | 46 |
| 2008 4 | 2 | 0 | 2 |
| 2008 3 | 3 | 0 | 3 |
| 2008 2 | 6 | 0 | 6 |
| 2008 1 | 7 | 0 | 7 |
Mostrar todo
